Efficacy and safety of CD19‐directed CAR‐T cell therapies in patients with relapsed/refractory aggressive B‐cell lymphomas: Observations from the JULIET, ZUMA‐1, and TRANSCEND trials

Chimeric antigen receptor (CAR)‐T cell therapies have improved the outcome for many patients with relapsed or refractory aggressive B‐cell lymphomas. In 2017, axicabtagene ciloleucel and soon after tisagenlecleucel became the first approved CAR‐T cell products for patients with high‐grade B‐cell lym...

Descripción completa

Detalles Bibliográficos
Autores principales: Westin, Jason R., Kersten, Marie José, Salles, Gilles, Abramson, Jeremy S., Schuster, Stephen J., Locke, Frederick L., Andreadis, Charalambos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Critical Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290945/
https://www.ncbi.nlm.nih.gov/pubmed/34310745
http://dx.doi.org/10.1002/ajh.26301

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290945/
https://www.ncbi.nlm.nih.gov/pubmed/34310745
http://dx.doi.org/10.1002/ajh.26301

Ejemplares similares